Jeff Yass’s Edgewise Therapeutics EWTX Stock Holding History

Jeff Yass’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.57M	Sell	38,600 -12,900	-25%	-$445K	﹤0.01%	7052
2026 Q1	$1.62M	Sell	51,500 -26,700	-34%	-$770K	﹤0.01%	6663
2025 Q4	$1.94M	Buy	78,200 +1,700	+2%	+$34.1K	﹤0.01%	5722
2025 Q3	$1.24M	Buy	76,500 +60,900	+390%	+$864K	﹤0.01%	6825
2025 Q2	$205K	Sell	15,600 -116,900	-88%	-$1.69M	﹤0.01%	11170
2025 Q1	$2.92M	Buy	132,500 +11,500	+10%	+$302K	﹤0.01%	4709
2024 Q4	$3.23M	Sell	121,000 -138,800	-53%	-$4.42M	﹤0.01%	4346
2024 Q3	$6.93M	Buy	259,800 +225,000	+647%	+$4.48M	﹤0.01%	3106
2024 Q2	$627K	Buy	+34,800	New	+$607K	﹤0.01%	7724
2023 Q3	–	Sell	-15,000	Closed	-$116K	–	12261
2023 Q2	$116K	Buy	+15,000	New	+$127K	﹤0.01%	10825

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's EWTX Position: Q2 2026 in Review

Jeff Yass reduced its Edgewise Therapeutics (EWTX) stake by 79% in Q2 2026, selling an estimated $723K and leaving 5,692 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #11646.

Jeff Yass first reported a position in EWTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $5.35M in Q3 2024. 224 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

Jeff Yass held 5,692 shares of Edgewise Therapeutics worth $231K as of Q2 2026.
Jeff Yass sold 20,982 Edgewise Therapeutics shares in Q2 2026, an estimated $723K.
Edgewise Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11646 holding.
Jeff Yass first reported a position in Edgewise Therapeutics in Q1 2023 and has held it in 13 quarters since.
Jeff Yass's Edgewise Therapeutics position peaked at $5.35M in Q3 2024.
224 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.